These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23550022)

  • 1. Stem cell maintenance and disease progression in chronic myeloid leukemia.
    Ito T
    Int J Hematol; 2013 Dec; 98(6):641-7. PubMed ID: 23550022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
    Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.
    Stefanachi A; Leonetti F; Nicolotti O; Catto M; Pisani L; Cellamare S; Altomare C; Carotti A
    Curr Cancer Drug Targets; 2012 Jun; 12(5):571-96. PubMed ID: 22414010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of Chronic Myeloid Leukemia in Mice.
    Zhang H; Li S
    Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
    Park CS; Lacorazza HD
    Exp Mol Med; 2020 Oct; 52(10):1663-1672. PubMed ID: 33067577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
    Peng C; Chen Y; Yang Z; Zhang H; Osterby L; Rosmarin AG; Li S
    Blood; 2010 Jan; 115(3):626-35. PubMed ID: 19965668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
    Rumpold H; Webersinke G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.
    Jørgensen HG; Holyoake TL
    Hematol Oncol; 2001 Sep; 19(3):89-106. PubMed ID: 11574931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.